Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + oxaliplatin versus cisplatin + fluorouracil as first-line treatment for stage IV squamous cell esophageal carcinoma
ChiCTR-TRC-13003643Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Gemcitabine + oxaliplatin with Cisplatin + fluorouracil control (2 arms). Primary endpoint: Progression-free survival. Started Oct 2013; status: completed.
02
Drugs
gemcitabineoxaliplatincisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13003643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003643.